SEC Form 4 · accession 0001127602-15-028796
Alkermes plc. · ALKS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elliot Ehrich
Officer — EVP, R&D & CMO, Alkermes, Inc.
Period of report
Oct 5, 2015
Accepted (ET)
Oct 7, 2015 · 5:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001520262
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Oct 5, 2015 | A | 5,000 | $0.00 | A | 36,302 | D | |
| Ordinary Shares | Oct 5, 2015 | F | 2,356 | $59.77 | D | 33,946 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Restricted Stock UnitsF1,F2 | — | Oct 5, 2015 | A | 5,000 | A | — | — | Ordinary Shares | 5,000 | 5,000 | D |
Explanation of responses
- F1Each performance restricted stock unit represents a contingent right to receive one ordinary share of Alkermes plc.
- F2Represents the earned but unvested portion of the performance restricted stock units granted to the reporting person on March 3, 2014. Fifty percent of the earned performance restricted stock units vested on October 5, 2015 and are included in Table I of this Form 4; the remaining fifty percent of the earned performance restricted stock units are included in Table II of this Form 4 and will vest on October 5, 2016. The performance restricted stock units were earned based on the Food and Drug Administration's approval of ARISTADA? (aripiprazole lauroxil).